ERBB2 and heart failure: However, in a pivotal trial involving ErbB-2-positive metastatic breast cancer patients treated with trastuzumab, 27% of patients exhibited some degree of cardiac impairment, including an asymptomatic decrease in left ventricular systolic function, and symptomatic heart failure in 19% of patients 10.